FDA has rejected Capricor’s Duchenne muscular dystrophy cell therapy deramiocel for a second time since 2025, citing “serious data integrity violations” that the agency says compromised study findings. The action underscores continued regulatory scrutiny of manufacturing and trial data quality for advanced cell therapies, where small documentation gaps can derail entire programs. Capricor did not receive the second approval pathway after the latest FDA assessment, leaving the program without an updated path to market. For developers and investors, the decision signals that regulators remain focused on traceability, audit readiness, and consistency across clinical and supporting datasets. The company’s next steps will likely depend on how it addresses the specific integrity failures identified by the agency and whether it can repackage the evidence under FDA’s review standards. Deramiocel’s repeated rejection also raises the bar for any downstream partners evaluating similar readouts and governance practices. For Duchenne stakeholders, the immediate impact is continued delay in potential therapeutic availability—particularly as the condition remains an area with intense competitive activity and high unmet need.